EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )

Lawrence F Eichenfield iD, Mercedes E Gonzalez, Mark Boguniewicz, Tracy Funk, Adelaide A Hebert iD, Vimal H Prajapati, Chesahna Kindred, Rocco Serrao, Lisa Swanson, David Krupa, Scott Snyder, Melissa S Seal und 3 weitere

Pediatric Dermatology · 2026-05 · 43 (3) · 642-649

DOI: 10.1111/pde.70177 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Pediatric Dermatology, online erschienen am 08.03.2026. Verfasst von Lawrence F Eichenfield und 14 weiteren Autor:innen. Beteiligte Einrichtung: Rady Children's Hospital-San Diego, Departments of Dermatology and Pediatrics, University of California San Diego-School of Medicine, San Diego, Cali…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Benzamides, Aminopyridines, Phosphodiesterase 4 Inhibitors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arcutis Biotherapeutics Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

INTEGUMENT‐PED/NCT04845620, a 4‐week, phase 3 trial, demonstrated efficacy and safety of roflumilast cream 0.05% in children aged 2–5 years with mild‐to‐moderate atopic dermatitis (AD). A phase 3 open‐label extension trial (INTEGUMENT‐OLE [NCT04804605]) investigated long‐term outcomes continuing roflumilast cream for ≤ 56 weeks.

Methods

Caregivers of eligible patients from INTEGUMENT‐PED applied roflumilast cream 0.05% once‐daily in INTEGUMENT‐OLE. Patients achieving Validated Investigator Global Assessment for AD (vIGA‐AD) clear (0) at/after week 4 of INTEGUMENT‐OLE switched to twice‐weekly (BIW) application. Evaluation of safety (adverse events [AEs] and application‐site tolerability) was the primary objective. Efficacy endpoints assessed from INTEGUMENT‐PED baseline included vIGA‐AD success (clear/almost clear [0/1] plus ≥ 2‐point improvement), vIGA‐AD 0/1, ≥ 75% improvement in Eczema Area and Severity Index, and Worst Itch‐Numeric Rating Scale success (≥ 4‐point improvement in patients with baseline score ≥ 4). Duration of vIGA‐AD 0/1 and sign/symptom control (“disease control”) with BIW application was determined.

Results

Among 562 patients, 14 (2.5%) had treatment‐related AEs reported. Roflumilast was well tolerated; application‐site pain AEs were reported for four (0.7%) patients. At treatment‐week 56, AD signs/symptoms continued to improve (63.1% of patients achieved vIGA‐AD 0/1). Of 170 (30.2%) patients who switched to BIW application, the median Kaplan–Meier duration of “disease control” was 238 days.

Conclusions

Roflumilast cream 0.05% demonstrated a favorable long‐term safety profile and durable efficacy for up to 56 weeks of treatment in children aged 2–5 years with AD, and “disease control” was maintained with BIW application. These results are consistent with previous studies, including patients aged ≥ 6 years from INTEGUMENT‐OLE. Trial Registration: Clinicaltrials.gov identifier: NCT04845620

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicBenzamidesAminopyridinesPhosphodiesterase 4 InhibitorsHumansCyclopropanesMaleFemaleChild, PreschoolTreatment OutcomeDrug Administration ScheduleSeverity of Illness IndexSkin CreamAdministration, Cutaneous

Stichwörter der Autor:innen

atopic dermatitischildreneczemapruritustopical roflumilast

Substanzen

RoflumilastCyclopropanesBenzamidesAminopyridinesPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Rady Children's Hospital-San Diego, Departments of Dermatology and Pediatrics, University of California San Diego-School of Medicine, San Diego, California, USA.
  • Pediatric Skin Research, LLC, Coral Gables, Florida, USA.
  • National Jewish Health, Denver, Colorado and University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.
  • UTHealth McGovern Medical School, Houston, Texas, USA.
  • Dermatology Research Institute, Skin Health & Wellness Centre, University of Calgary, and Probity Medical Research, Calgary, Alberta, Canada.

ORCID-Profile: Lawrence F Eichenfield, Adelaide A Hebert

Förderung

  • Arcutis Biotherapeutics Inc.

Zitieren

APA

Eichenfield, L. F., Gonzalez, M. E., Boguniewicz, M., Funk, T., Hebert, A. A., Prajapati, V. H., Kindred, C., Serrao, R., Swanson, L., Krupa, D., Snyder, S., Seal, M. S., Hanna, D., Burnett, P., & Berk, D. R. (2026). Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE ). Pediatric Dermatology, 43(3), 642-649. https://doi.org/10.1111/pde.70177

Vancouver

Eichenfield LF, Gonzalez ME, Boguniewicz M, Funk T, Hebert AA, Prajapati VH, et al. Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE ). Pediatric Dermatology. 2026;43(3):642-649. doi:10.1111/pde.70177

BibTeX
@article{Eichenfield2026,
  author = {Eichenfield, Lawrence F and Gonzalez, Mercedes E and Boguniewicz, Mark and Funk, Tracy and Hebert, Adelaide A and Prajapati, Vimal H and Kindred, Chesahna and Serrao, Rocco and Swanson, Lisa and Krupa, David and Snyder, Scott and Seal, Melissa S and Hanna, Diane and Burnett, Patrick and Berk, David R},
  title = {Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )},
  journal = {Pediatric Dermatology},
  year = {2026},
  volume = {43},
  number = {3},
  pages = {642--649},
  doi = {10.1111/pde.70177}
}
Kostenlos starten →